Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab," Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that the
long-term data from a global phase II study (the XCIMA study) for
nemolizumab (CIM331) was published in Journal of Allergy and Clinical
Immunology Online on May 9, 2018.
“Nemolizumab in moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study” Kenji Kabashima, M.D., Ph.D., et al
“Control of chronic pruritus and inflammation of the skin is crucial for patients with atopic dermatitis (AD). This long-term extension data which demonstrated efficacy and safety of nemolizumab reinforced anticipation that nemolizumab may offer a novel treatment option for the disease,” said Dr. Yasushi Ito, Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “Chugai’s mission is to contribute to patients through innovative medicines. We will closely work together with our partners - Galderma and Maruho, towards helping AD patients by developing this new treatment option as quickly as possible.”
“I am delighted to see a steady development of the novel treatment which addresses pathogenesis of pruritus in atopic dermatitis,” said, Professor Kenji Kabashima, Kyoto University, the first author of the article. “I would like to carefully examine safety and efficacy of nemolizumab further, in the expectation of future clinical use.”
The study was conducted to evaluate safety and efficacy of nemolizumab in 264 patients with moderate-to-severe AD. The safety and efficacy of nemolizumab at 12 weeks, the study’s primary endpoint, were confirmed and published in The New England Journal of Medicine Online in March 2017. The data published this time was obtained to assess safety and efficacy of long-term administration. It confirmed that nemolizumab maintained its safety and efficacy after one year of continuous treatment.
About the results of the global phase II study
Press release issued in March 2, 2017.
Chugai granted the exclusive development and marketing rights of nemolizumab worldwide, excluding Japan and Taiwan, to Galderma and licensed out the development and marketing rights in the skin disease area to Maruho for the Japanese market respectively. Currently, Galderma is conducting a phase 2b study and Maruho is conducting a phase 3 study.
Please refer to the press release for the details of the license
About nemolizumab (CIM331)
Nemolizumab (CIM331) is a humanized anti-human IL-31 receptor A (IL-31RA) monoclonal antibody intending to be a first-in-class treatment. IL-31 is identified as a pro-inflammatory cytokine that can induce pruritus, inflammation, and skin barrier dysfunction in atopic dermatitis, as well as pruritus in dialysis patients1, 2, 3, 4). Nemolizumab is thought to work by inhibiting biological activity of IL-31 through competitively blocking the binding of IL-31 to its receptor.
Trademarks used or mentioned in this release are protected by law.
1. Sonkoly E, et al., IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-7.
2. Cornelissen C, et al., IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clinical Immunol 2012; 129: 426-33.
3. Kasraie S, et al., Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 2010; 65: 712-21.
4. Ko MJ, et al., Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol 2014; 71: 1151-9.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LifeSpan BioSciences Announces the Acquisition of Everest Biotech16.7.2019 08:00:00 CEST | Press release
LifeSpan BioSciences (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Everest Biotech. Everest Biotech are ISO 9001:2015 certified experts in antigen affinity purified goat polyclonal antibodies. The acquisition of Everest Biotech further expands LSBio’s product offering and strengthens the company’s position as one of the fastest growing providers in the research reagent market. Through its partnerships, LSBio now offers a comprehensive catalogue of reagents that can be coupled with their extensive collection of IHC validated primary antibodies. “We are looking forward to adding the Everest Biotech product range to the LSBio portfolio,” said Heather Holemon, CEO of LSBio. “Everest Biotech products are of exceptionally high quality and perfectly complement our existing portfolio.” The Everest Biotech commitment to quality and continuous improvement has ensured the growth of their catalogue, which now contains thous
AppyParking Closes £7.6 Million Series A Funding16.7.2019 07:00:00 CEST | Press release
AppyParking, the kerbside management and mobility technology firm that is transforming parking for motorists and empowering local authorities and car park operators to better manage their assets, announced that the company has just closed a £7.6 million Series A round. The funding round includes new strategic investment from Hyundai Motor Company and Sumitomo Corporation. It was led by West Hill Capital, the London based venture capital firm, with participation from existing investors Aviva Ventures and Breed Reply. The investment brings AppyParking’s total funding since launch to over £11 million and will enable the company to accelerate product development, support domestic and international growth and continue to expand their talented team. Founded in 2013 with the launch of their award-winning smart parking app, AppyParking is on a mission to make parking forgettable and help prepare cities for the rise of autonomous vehicles. They were the first company in the world to focus on th
Dubai to Organise Global Investment in Aviation Summit in January 202016.7.2019 07:00:00 CEST | Press release
The General Civil Aviation Authority (GCAA) of UAE has announced that the second edition of Global Investment in Aviation Summit (GIAS) 2020, themed ‘Enabling Global Aviation Growth through Fund Raising and Key Partnerships’ will be held in Dubai from January 27-29. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190716005136/en/ Saif Mohammed Al Suwaidi, Director General of the GCAA (Photo: AETOSWire) Over 200 investors and 1,200 delegates, besides selected government officials, aviation organisations, finance & insurance firms, aviation asset owners, aircraft operators & logistic service providers and legal consultants are expected to turn up at the event. While disclosing the details of the summit Saif Mohammed Al Suwaidi, Director General of the GCAA, highlighted the UAE’s remarkable position in the international and regional aviation industry. Al Suwaidi said, “The national agenda for 2021 aims for UAE to be the world fi
Our Toy Stories @ Harbour City16.7.2019 02:13:00 CEST | Press release
While Disney and Pixar’s “Toy Story 4” is hitting the big screens around the world this summer, Harbour City, the largest shopping mall in Hong Kong, is joining forces with Disney to bring the movie to life from now till 4 August, 2019! Inspired by the movie, Harbour City has transformed into a “Toy Story” themed carnival with different games and challenges at Ocean Terminal Forecourt next to Star Ferry Pier and Ocean Terminal Deck with stunning Victoria Harbour view, where fans can play with Woody and the gang under the best Harbour & Sunset views in Hong Kong! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005854/en/ Large Scale Toy Story Carnival at Harbour City in Hong Kong (Photo: Business Wire) Additionally, fans can experience other fun, immersive activities throughout the mall including The Art of Toy Story 4 exhibit, kids’ workshops, “Toy Story 4” pop-up store, along with a “Toy Story” themed dessert pop-up st
HSEVEN Accelerate World-Class African Startups16.7.2019 01:00:00 CEST | Press release
HSEVEN, Africa’s largest accelerator is launching “HSEVEN DISRUPT AFRICA”, an ambitious startup acceleration program designed for entrepreneurs of the Moroccan and African diaspora. The 6-month program will provide a seed investment of €150,000 plus an eventual investment of €500,000 to €1.5 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005770/en/ HSEVEN team (Photo: AETOSWire) HSEVEN DISRUPT AFRICA is designed to support exceptional entrepreneurs building high-impact startups, and targets seed and early stage startups with 2 to 5 founders that are eager to impact Africa through innovative services, products and business models. The program will start with a global call for applications, followed by an international selection roadshow in New York, Montréal, San Francisco, Shanghai, Dubaï, Londres, Amsterdam, Paris, Casablanca. The selected startups will benefit from a seed investment of €150,000 at the beginn
PayPal Expands its International Money Transfer Service Xoom to 32 Markets across Europe15.7.2019 23:01:00 CEST | Press release
Today, PayPal launched Xoom—its international money transfer service—in 32 markets1 across Europe. People in these markets can now use Xoom to quickly send money, pay bills or top up phones to more than 130 markets internationally. Xoom’s expansion to Europe is a significant milestone and another example of PayPal fulfilling its mission to make the movement and management of money more convenient, accessible, secure and affordable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005823/en/ Xoom Launches in 32 Markets Across Europe (Photo: Business Wire) The global remittance market reached $689 billion in 2018, up from $633 billion in 2017 according to World Bank data2. In 2019, remittance flows to low- and middle-income countries are expected to reach $550 billion, to become their largest source of external financing. The global average cost of sending $200 remained high, at around 7 percent in the first quarter of 201